StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

TRVN opened at $1.71 on Tuesday. Trevena has a 1-year low of $1.13 and a 1-year high of $19.23. The company’s fifty day moving average price is $1.71 and its two-hundred day moving average price is $3.29.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter. Equities analysts forecast that Trevena will post -23.04 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.